China’s top drug regulator is planning to impose more stringent rules on how conditional approval, the equivalent of the US Food and Drug Administration’s accelerated approval scheme, will be granted after a more than two-year trial of the program.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?